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I.

INTRODUCTION
“It is a chemical entity, but DNA’s importance flows from its ability
to encode and transmit the instructions for creating humans. Life’s
instructions ought not be controlled by legal monopolies created at the
whim of Congress or the courts,” wrote Dr. James Watson, one of the
Physiology or Medicine Nobel Prize winners in 1962 for the discovery of
the structure of DNA.1 Dr. Watson also proclaimed, “[i]n years to come,
with the right advances in genetic engineering, we may well be able to
treat or rectify mental disabilities and physical diseases which today are
deemed incurable. Such hope is all the more reason that scientific
research on human genes should not be impeded by the existence of
unnecessary patents.”2 Indeed this viewpoint may be well-reasoned, but
determining whether a patent is necessary or unnecessary is far too
subjective to be reasonably practical.
Patents are fundamentally necessary for advancements in scientific
research; stating anything to the contrary opposes both reality and the
patent system’s purpose.3 However, after the Supreme Court decision
that largely abolished gene patentability, the recent Federal Circuit
decision, and new patent laws there are unresolved questions as to the
extent patents in the field of genetic testing will continue to exist and what
the future holds for the underlying research.4 The biotechnology industry
has been shaken to its core numerous times over the past several years,
and there is mounting pressure for stability, which is likely only
obtainable through a legislative solution.5 While this Note does not
1 Brief for James D. Watson as Amici Curiae Supporting Neither Party at 2, Ass’n for
Molecular Pathology v. USPTO, 689 F.3d 1303 (2012) (No. 2010-1406), available at
https://www.aclu.org/files/assets/2012_06_15_-_james_d__watson_brief_on_remand.pdf;
James
Watson
–
Biographical,
NOBELPRIZE.ORG,
http://www.nobelprize.org/nobel_prizes/medicine/laureates/1962/watson-bio.html
(last
visited Oct. 30, 2013).
2 Brief for James D. Watson, supra note 1, at 6 (emphasis added).
3 Adrian Tombling, Ban on Human Gene Patents is Baffling but it Won’t Impede Biotech
Research,
THE
GUARDIAN
(June
18,
2013,
8:51
PM),
http://www.theguardian.com/science/blog/2013/jun/18/ban-human-gene-patents-biotechresearch.
4 Ass’n for Molecular Pathology v. Myriad Genetics, Inc., 133 S. Ct. 2107 (2013);
BRCA1- & BRCA2-Based Hereditary Cancer Test Patent Litig. v. Ambry Genetics Corp.,
2014 U.S. App. LEXIS 23692, at *1 (Fed. Cir. Dec. 17, 2014).
5 Austin Donohue, USPTO Issues New Myriad Guidance, BIOTECHNOW (Feb. 4, 2015),
http://www.biotech-now.org/public-policy/patently-biotech/2015/02/bio-deputy-generalcounsel-remarks-on-revised-eligibility-guidance (“If anything, this decision . . . is a reminder
that the PTO’s efforts to bring stability to this area of the law could easily be undone by the
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propose such legislation, this Note nonetheless addresses several
practical implications affecting the industry and patent-holders as a result
of the Supreme Court holding that isolated genes are unpatentable and
the Federal Circuit holding that part of Myriad’s patent-eligible subject
matter did not add enough to wholly make the genetic testing claims
patent-eligible .6
Specifically, this Note addresses how new provisions in the LeahySmith America Invents Act (“AIA”) changed the practice of patent law
and considerations that courts need to be cognizant of when issuing future
rulings. Part II delves into the fundamentals of patent law that pertain to
the subsequent discussion and sets the stage for the notion that obtaining
a patent does not unequivocally grant absolute rights. Part III addresses
the background case law that led to the recent monumental Supreme
Court decision, Ass’n for Molecular Pathology v. Myriad Genetics, Inc.,7
the series of guidance issued by the United States Patent and Trademark
Office (“USPTO”), and the most recent authority from the Federal Circuit
in BRCA1- & BRCA2-Based Hereditary Cancer Test Patent Litig. v.
Ambry Genetics Corp.8 Part IV discusses the AIA and how it altered the
practice of patent law with respect to procedures for challenging the
validity of patents within the USPTO itself through post-grant
proceedings. Part V highlights that these new post-grant proceedings
alongside Myriad lead to less obvious, but still significant trouble for the
industry’s leading patent-holders. Finally, this Note concludes that the
practice of patent law is at a very pivotal and delicate point and that it
must evolve to continue promoting research generally, and specifically in
the genetic testing industry. This will be accomplished if genetic tests,
as so-called methods, remain patent-eligible subject matter despite the
fact that genes are now unpatentable.

next Federal Circuit decision, or the one after that. We are afraid that we will be prosecuting
applications on a shifting slate for some time to come. We need a more stable solution going
forward.”).
6 Myriad Genetics, Inc., 133 S. Ct. at 2107; Ambry Genetics Corp., 2014 U.S. App.
LEXIS 23692, at *20.
7 Myriad Genetics, Inc., 133 S. Ct. at 2107.
8 Ambry Genetics Corp., 2014 U.S. App. LEXIS 23692, at *1; Memorandum from
Andrew H. Hirshfeld, Deputy Commissioner for Patent Examination Policy, for Patent
Examining
Corps
(Mar.
4,
2014),
available
at
http://www.uspto.gov/patents/law/exam/myriad-mayo_guidance.pdf.
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II. PATENT LAW BACKGROUND
Pursuant to the Constitution, “Congress shall have the power to . . .
promote the [p]rogress of [s]cience and useful [a]rts, by securing for
limited [t]imes to [a]uthors and [i]nventors the exclusive [r]ight to their
respective [w]ritings and [d]iscoveries.”9 This provision gave rise to the
United States Patent Act of 1790, from which the first patents were born.10
A patent is defined as a “property right granted by the Government of the
United States of America to an inventor []to exclude others from making,
using, offering for sale, or selling the invention throughout the United
States . . . for a limited time in exchange for public disclosure of the
invention.”11 The United States Patent Act was largely unchanged until
1952 when the USPTO began classifying patents into three categories:
utility patents, design patents, and plant patents.12 The general focus of
this Note is on utility patents, which are granted for the invention of “a
new and useful method, process, machine, device, manufactured item, or
chemical compound” or any new and useful improvement thereof.13 In
modern times, courts categorize chemical compounds as compositions of
matter and define them as tangible items comprising two or more
substances.14 On the other hand, a patented method consists of a series of
steps that is only infringed upon if each and every step is performed.
In order to receive a utility patent, an inventor publicly discloses his
invention in exchange for a twenty-year period of exclusivity to use and
practice the invention from the date that the patent application is filed
with the USPTO.15 Through the lengthy process of obtaining a patent, the
inventor submits to the USPTO a patent application ideally containing
claims that specifically identify the proposed invention. At the USPTO,

9

U.S CONST. art. I, § 8, cl. 8.
Press Release, USPTO, The U.S. Patent System Celebrates 212 Years, #02-26 (Apr. 9,
2002), available at http://www.uspto.gov/news/pr/2002/02-26.jsp.
11 Patent FAQs, USPTO, http://www.uspto.gov/inventors/patents.jsp (last visited Apr.
19, 2014).
12 “A patent for an invention is the grant of a property right to the inventor, issued by the
United States Patent and Trademark Office.” General Information Concerning Patents,
USPTO (Oct. 2014), http://www.uspto.gov/patents-getting-started/general-informationconcerning-patents.
13 Mary
Bellis,
Utility
Patent,
ABOUT.COM,
http://inventors.about.com/od/definations/g/Utility_Patent.htm (last visited May 13, 2015).
14 35 U.S.C. § 101 (2012); Andrew Chadeayne, Composition of Matter Claims,
INVENTING PATENTS (Sept. 17, 2013), http://inventingpatents.com/composition-matterclaims/.
15 35 U.S.C. § 154(a)(2) (2012).
10
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a patent examiner (“examiner”) reviews the patent application, and the
invention is publicly disclosed when the USPTO publishes the patent
application eighteen months after it is filed.16
The examiners
communicate with inventors by sending office actions that include the
examiner’s detailed analysis of the patent application, including reasons
the inventor cannot yet receive a patent for the particular invention.17 For
patent applications that adhere to all applicable provisions, examiners
will issue a notice of allowance resulting in the grant of a patent, provided
that the inventor pays the issue fee.18 The Supreme Court case Myriad, a
focal point of this Note, deals primarily with one of those provisions for
patentability—whether the subject matter itself is patentable.
Generally speaking, Myriad pertains to “patent-eligible” subject
matter defined under 35 U.S.C. § 101.19 This provision identifies four
categories of patent-eligible subject matter: a process, a machine, a
manufacture, and a composition of matter.20 Everything within the scope
of a utility patent must fall within at least one of these four categories. 21
Genes, chemical compounds or compositions of matter, defined as the
basic units of heredity responsible for all physical and inheritable
characteristics of an organism, were therefore claimed in utility patents. 22
Examples of patent ineligible subject matter, or the so-called judicial
exceptions, include: “laws of nature, physical or natural phenomenon,
and abstract ideas.”23 Once an examiner or a court finds that claims are
patent-eligible, the patentability inquiry proceeds to other provisions that,
16

Id. § 122(b)(1) (explaining that patent applications are published eighteen months after
filing and once published they are easily accessible on websites such as
GOOGLE.COM/PATENTS or HTTP://PORTAL.USPTO.GOV/PAIR/PUBLICPAIR); Nonprovisional
(Utility)
Patent
Application
Filing
Guide,
USPTO
(Jan.
2014),
http://www.uspto.gov/patents/resources/types/utility.jsp.
17 37 C.F.R. § 1.104 (2014).
18 Id. § 1.311 (2014).
19 35 U.S.C. § 101 (2012); Ass’n for Molecular Pathology v. Myriad Genetics, Inc., 133
S. Ct. 2107 (2013).
20 35 U.S.C. § 101.
21 Id.; Z. Peter Sawicki, Visala C. Goswitz & Amanda Prose, Patenting Biologicals:
Myriad Issues and Options in the Wake of Myriad, BENCH & B. OF MINN., 24 (Sept. 2013),
available at http://mnbenchbar-digital.com/mnbenchbar/september_2013?pg=24#pg24.
22 Gene, DICTIONARY.COM, http://dictionary.reference.com/browse/gene (last visited
Mar. 22, 2014); General Information Concerning Patents, supra note 12 (“A patent for an
invention is the grant of a property right to the inventor, issued by the United States Patent
and Trademark Office.”).
23 Bilski v. Kappos, 130 S. Ct. 3218, 3225 (2010) (quoting Diamond v. Chakrabarty, 447
U.S. 303, 309 (1980)).
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for instance, assess novelty and nonobviousness.24
For over thirty years before Myriad, the USPTO granted thousands
of gene patents as compositions of matter.25 The USPTO even reaffirmed
the issuance of such patents in 2001.26 But in Myriad, the Court
essentially held that patents may no longer be granted for the simple
discovery that a particular human gene sequence corresponds to a specific
inheritable trait.27 Thus, without expressly acknowledging Dr. Watson’s
views, the Court fundamentally agreed with him that genes should not be
patentable, not because patents on genes are unnecessary, but because the
discovery of a gene is unpatentable.28 However, courts have yet to abolish
the patentability of genetic tests.29 The unresolved debate, then, is over
whether the patentability of genetic tests has been implicitly abolished
under certain circumstances.30 Myriad put forth a tremendous effort
trying to maintain its foothold in this industry, but it seems these battles
are ones that Myriad will not win.31
Settlements of some disputes, along with the USPTO guidance and
Ambry, leave the industry in a greater state of uncertainty in early 2015
than on June 13, 2013 when Myriad was decided.32 Ambry signals early
signs of trouble for the genetic testing industry because it shows courts
will not hesitate to extend the unpatentability of genes to the also
previously patentable methods that use those genes.33 As such, Ambry
demonstrates how crucial the underlying patentability of genes was for
the patentability of genetic tests of those genes.34 It may now be just a
24

35 U.S.C. §§ 102, 103 (2012).
Eric J. Rogers, Can You Patent Genes? Yes and No, 93 J. PAT. & TRADEMARK OFF.
SOC’Y 19 (2010).
26 66 Fed. Reg. 1092, 1092–94 (Jan. 5, 2001).
27 Ass’n for Molecular Pathology v. Myriad Genetics, Inc., 133 S. Ct. 2107 (2013).
28 Id.
29 Intellectual Property and Genomics, NAT’L GENOME HUMAN RESEARCH INST.,
http://www.genome.gov/19016590 (last updated Oct. 30, 2014).
30 Leila Gray, U.S. Supreme Court Decision to Bar Gene Patents Opens Genetic Test
Options, UW TODAY (June 20, 2013), http://www.washington.edu/news/2013/06/20/u-ssupreme-court-decision-opens-genetic-test-options/.
31 Andrew Pollack, Myriad Genetics Ending Patent Dispute on Breast Cancer Risk
Testing, N.Y. TIMES (Jan. 27, 2015), http://www.nytimes.com/2015/01/28/business/myriadgenetics-ending-patent-dispute-on-breast-cancer-risk-testing.html?_r=0.
32 Id.
33 Myriad Genetics, Inc., 133 S. Ct. at 2107; BRCA1- & BRCA2-Based Hereditary
Cancer Test Patent Litig. v. Ambry Genetics Corp., 2014 U.S. App. LEXIS 23692, at *1 (Fed.
Cir. Dec. 17, 2014).
34 Id.
25
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matter of time before genetic tests are unpatentable solely because genes
themselves are unpatentable.
III. MYRIAD AND PATENT-ELIGIBLE SUBJECT MATTER
A. Recent Case Law
On June 16, 1980, the Supreme Court decided its first modern-day
pivotal case in the area of patent-eligible subject matter.35 In Diamond v.
Chakrabarty,36 the Court ruled “[a] live, human-made micro-organism is
patentable subject matter under § 101.”37 Reviewing the legislative
history, the Court opined that “Congress contemplated that patent laws
should be given wide scope, and . . . broad construction. While laws of
nature, physical phenomena, and abstract ideas are not patentable [the
claims here are to a] composition of matter — a product of human
ingenuity ‘having a distinctive name, character[, and] use.’”38 This
opinion was revolutionary for its time because a patent examiner
previously rejected this patent application on the grounds that
microorganisms are products of nature and that living things, such as
microorganisms, are unpatentable subject matter.39 Yet, central to the
Court rejecting that analysis, the inventor produced a new bacterium that
had “markedly different characteristics” from bacteria found in nature. 40
The Court classified the bacterium as patent-eligible subject matter
because those characteristics have the potential for significant utility. 41
Importantly, the Court explained that not all differences between
something that is produced and something that is found in nature give rise
to the level of “marked differences.”42 “Marked differences” must be
“significant differences,” which are more than merely incidental or
trivial.43
Three decades later, in Bilski v. Kappos,44 the Court found that a
claimed process to hedge risk in the energy business was unpatentable
subject matter, and thus invalid, when it involved an abstract idea that
35
36
37
38
39
40
41
42
43
44

Diamond v. Chakrabarty, 447 U.S. 303 (1980).
Id.
Id. at 305, 310.
Id. (quoting Hartranft v. Wiegmann, 121 U.S. 609, 615 (1887)).
Id. at 306.
Id. at 310–11.
Diamond, 447 U.S. at 310–11.
Memorandum from Andrew H. Hirshfeld (Mar. 4, 2014), supra note 8.
Id.
130 S. Ct. 3218, 3231 (2010).

SAM BERSE.DOCX (DO NOT DELETE)

424

SETON HALL LEGISLATIVE JOURNAL

11/3/2015 3:50 PM

[Vol. 39:2

broadly preempted its use in all fields.45 Processes are patentable subject
matter under 35 U.S.C. § 101, but in this case, the process was
unpatentable because “[h]edging is a fundamental economic practice long
prevalent in our system of commerce and taught in any introductory
finance class.”46 The Court opined that the 1952 Patent Act did not
expand the scope of patentable subject matter to include any series of
steps as a process under 35 U.S.C. § 101, and that “[t]he patent
application here can be rejected under our precedents on the
unpatentability of abstract ideas.”47
Two years after Bilksi, the Supreme Court held in Mayo
Collaborative Services v. Prometheus Laboratories,48 that Prometheus’
medical test, which determined the proper dosage of a particular drug by
measuring levels of the drug’s metabolites in a patient’s system, was not
patentable.49 The Court reasoned that the processes covered by
Prometheus’ patents did not transform otherwise unpatentable natural
laws—in this case the correlation between the levels of the drug’s
metabolites in the patient’s system with respect to the proper dosage the
patient should be given—into patent-eligible applications complying
with 35 U.S.C. § 101.50 Laws of nature, in addition to abstract ideas, are
expressly excluded from that definition.51 In the instance of Prometheus’
medical test, the Court also found that the claims merely contained steps
that involved “well-understood, routine, conventional activity previously
engaged in by researchers in the field.”52 As a result, Prometheus’ patents
were invalid, especially in light of Bilski.
In a sense, invalidation is a way of stating that the examiners should
not have granted either an entire patent or some claims therein; invalid
claims are unenforceable against another entity for the purpose of an

45

See Mayo Collaborative Servs. v. Prometheus Labs., 132 S. Ct. 1289, 1305 (2012).
35 USC § 101 (2012); Bilski, 130 S. Ct. at 3231 (Rader, J., dissenting) (quoting In re
Bilski, 545 F.3d 943, 1013 (2008)) (citing DIMITRIS N. CHORAFAS, INTRODUCTION TO
DERIVATIVE FINANCIAL INSTRUMENTS 75–94 (2008); S. ROSS, R. WESTERFIELD, & B. JORDAN,
FUNDAMENTALS OF CORPORATE FINANCE, 743–44 (8th ed. 2008); C. STICKNEY, R. WEIL, K.
SCHIPPER, & J. FRANCIS, FINANCIAL ACCOUNTING: AN INTRODUCTION TO CONCEPTS,
METHODS, AND USES, 581–82 (13th ed. 2010)).
47 Bilski, 130 S. Ct. at 3231, 3249.
48 132 S. Ct. 1289 (2012).
49 Id. at 1294.
50
Id.
51 Diamond v. Chakrabarty, 447 U.S. 303, 309 (1980).
52 Mayo, 132 S. Ct. at 1305.
46
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infringement lawsuit.53 For example, according to Bilski and Prometheus,
when the USPTO or courts invalidate a patent or some of its claims, the
invalidated portions become worthless. With that consideration in mind,
the focus of this Note now turns to the keystone case-line involving
Myriad Genetics, Inc. and its patents containing claims that are being
litigated in numerous district courts.
In 1996, Myriad Genetics located and sequenced two cancer
susceptibility genes known as BRCA1 and BRCA2.54 Myriad developed
and patented a genetic test for mutations in these genes and threatened to
sue doctors and institutions that were using the BRCA deoxyribonucleic
acid (“DNA”) sequences to test patients for genetic predisposition to
breast, ovarian, and prostate cancer.55 The American Civil Liberties
Union, the Association of Molecular Pathology, and several individual
doctors, genetic counselors, scientific researchers, and patients
challenged Myriad’s patents, arguing that human genes are not patenteligible and that certain patent claims were invalid.56 Finding that all of
Myriad’s asserted DNA claims were products of nature and therefore
patent ineligible under 35 U.S.C. § 101, the district court ruled against
Myriad, but the Federal Circuit reversed on appeal.57 The Supreme Court
granted certiorari, reaffirmed the district court’s holding by vacating the
judgment of the Federal Circuit, and remanded the case to the Federal
Circuit for further consideration in light of Prometheus.58
On remand, a three-judge panel for the Federal Circuit again held
that genomic DNA and the synthetic DNA molecule known as
complementary DNA (“cDNA”) are both patent-eligible.59 The judges
reasoned that genomic DNA can be extracted from its cellular
environment using a number of well-established laboratory techniques,
and a particular segment of DNA, such as a gene, can be excised or

53 Mary L. Miller & Richard P. Vitek, Validity and Invalidity of Patent Claims, TECH.
TRANSFER
PRAC.
MANUAL,
available
at
http://www.autm.net/AM/Template.cfm?Section=Volume_3_TOC&Template=/CM/Conten
tDisplay.cfm&ContentID=2207.
54 Dorothy R. Auth, ‘Myriad’ Aftermath: What Remains Patent Eligible?, 250 N.Y. L.J.
6 (2013).
55 Id.
56 Id.
57 Ass’n for Molecular Pathology v. USPTO, 689 F.3d 1303 (Fed. Cir. 2012); Ass’n for
Molecular Pathology v. USPTO, 653 F.3d 1329 (Fed. Cir. 2011).
58 Ass’n for Molecular Pathology v. USPTO, 132 S. Ct. 1794, 1794 (2012).
59 Ass’n for Molecular Pathology, 689 F.3d at 1326.
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amplified from the DNA to obtain the isolated DNA segment of interest. 60
Likewise, DNA molecules can also be synthesized in a laboratory. 61
However, in several processes analogous to those that occur in cells,
naturally occurring sequences of genetic information serve as the
template to create cDNA, a molecule that does not naturally exist because
it is not a direct copy of the DNA sequence that it complements.62 As a
result, the judges issued divergent opinions that raised questions about
the precise contours of DNA’s patent eligibility, especially with respect
to cDNA’s patent eligibility.63
Judge Alan D. Lourie’s majority opinion upheld Myriad’s BRCA
DNA claims on the grounds that the chemical differences generated
during the isolation process between naturally occurring and isolated
DNA sequences created a non-naturally occurring molecule.64 The claims
at issue were from U.S. Patent 5,747,282, and recited:
1. An isolated DNA coding for a BRCA1 polypep[]tide, said polypeptide having
the amino acid sequence set forth in SEQ ID NO:2.
2. The isolated DNA of claim 1, wherein said DNA has the nucleotide sequence
set forth in SEQ ID NO:1.
65
5. An isolated DNA having at least 15 nucleotides of the DNA of claim 1.

“SEQ ID NO:1” and “SEQ ID NO:2” correspond to the BRCA1 DNA
coding region and the BRCA1 protein, respectively, and in Judge
Lourie’s opinion the isolated DNA removed from its native cellular
environment was manipulated in such a way that it was markedly
different from what exists inside the body.66 Underscoring this notion was
the idea that “courts must be cautious before adopting changes that
disrupt the settled expectations of the inventing community.”67
Judge Kimberly A. Moore joined the majority’s opinion for cDNA
sequences, and concurred in judgment with respect to isolated DNA
sequences, but wrote separately to explain her reasoning based on the
USPTO’s history of awarding gene patents and the reliance interest of
60

Id. at 1313.
Id.
62 Id. at 1313–14 (explaining that cDNA is generated from mRNA, and therefore only
contains the coding regions of DNA known as exons, while DNA itself contains both exons
and non-coding regions known as introns).
63 Auth, supra note 54.
64 Ass’n for Molecular Pathology, 689 F.3d at 1336.
65 Id. at 1309; U.S. Patent No. 5,747,282 col. 153 (filed June 7, 1995).
66 Ass’n for Molecular Pathology, 689 F.3d at 1328.
67 Id. at 1333 (citing Warner-Jenkinson Co. v. Hilton Davis Chem. Co., 520 U.S. 17, 28
(1997)); see also Ariad Pharms., Inc. v. Eli Lilly & Co., 598 F.3d 1336, 1347 (Fed. Cir.
2010) (en banc).
61
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patent holders.68 Judge Moore opined that “to the extent the majority rests
its conclusion on the chemical differences between genomic and isolated
DNA (breaking the covalent bonds), I cannot agree that this is sufficient
to hold that the claims to human genes are directed to patentable subject
matter.”69 If this case were decided on a blank canvas, Judge Moore may
have concluded that isolated DNA is not patentable subject matter, and
yet again she echoes the majority’s sentiment that “we must be
particularly wary of expanding the judicial exception to patentable
subject matter where both settled expectations and extensive property
rights are involved.”70
Judge William C. Bryson, concurring in part and dissenting in part,
argued the genetic similarities between naturally occurring and isolated
BRCA DNA dwarfed any chemical differences between the two.71 Judge
Bryson believed that although Myriad had valid claims to cDNA, Myriad
did not have valid claims to the BRCA genes and associated gene
fragments.72 In Judge Bryson’s opinion, “Myriad’s claims to the isolated
BRCA genes seem . . . to fall clearly on the ‘unpatentable’ side of the line
the Court drew in Chakrabarty. Myriad is claiming the genes
themselves, which appear in nature on the chromosomes of living human
beings.”73 Judge Bryson concluded that “[o]ur role is to interpret the law
that Congress has written in accordance with the governing precedents”
and that “[t]here is no collective right of adverse possession to intellectual
property, and we should not create one.”74 Given that Judge Bryson
would affirm the district court’s rulings as to the BRCA gene and BRCA
gene segment claims, which ruled that DNA is patent ineligible subject
matter, these divergent positions set the stage for a subsequent appeal to
the Supreme Court.75
In the most recent iteration of Myriad, the Supreme Court addressed
the question of whether Myriad’s patents and claims to isolated BRCA1
and BRCA2 genes gave Myriad the exclusive right to isolate an
individual’s BRCA genes.76 The Court held that “separating [a] gene
68
69
70
71
72
73
74
75
76

Ass’n for Molecular Pathology, 689 F.3d at 1337.
Id. at 1341.
Id. at 1343.
Id. at 1355.
Id. at 1348.
Id. at 1350.
Ass’n for Molecular Pathology, 689 F.3d at 1350, 1358.
Id.; Auth, supra note 54.
Ass’n for Molecular Pathology v. Myriad Genetics, Inc., 133 S. Ct. 2107, 2116 (2013).
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from its surrounding genetic material is not an act of invention,” and that
genes isolated from human DNA claimed in Myriad’s patents were not
patentable because the “location and order” of the molecules in those
genes “existed in nature before Myriad found them” even though the
process of isolating nucleic acids, the building blocks of DNA, involves
changing their structure by breaking chemical bonds.77 Now, isolated
genomic DNA is classified as a patent ineligible product of nature under
35 U.S.C. § 101.78 However, cDNA is still patent-eligible because it is
not naturally occurring.79 The Supreme Court’s holding therefore upheld
the patentability of cDNA, but reversed the Federal Circuit’s
determination of the patentability of isolated DNA.80
For the first time, the Court made it exceedingly clear that Myriad’s
mere discovery of the precise location and genetic sequence of BRCA1
and BRCA2 within chromosomes 17 and 13 did not amount to a
patentable invention.81 Myriad nonetheless maintained its claims to
cDNA despite losing five of its 520 patent claims to BRCA1 and BRCA2
DNA, including the three claims previously discussed.82 The Court
agreed that cDNA is patent-eligible because cDNA is synthesized in such
a way that it is non-naturally occurring and is not simply isolated.83 Thus,
cDNA evaded the law of nature exception to patent eligibility. 84
Through Myriad, the Supreme Court clarified that it will not eagerly
defer to existing patent law practice and that it may render opinions
contrary to the desires of the USPTO or even the Federal Circuit.85 As an
example, when considering the patent eligibility of a small molecule or
protein isolated or purified from a natural source, the latest edition of the
USPTO’s MPEP instructs that “[p]urer forms of known products may be
patentable” and that “[p]ure materials are novel vis-à-vis less pure or
77 Id.; see Brian Resnick, Why is Myriad Genetics Still Filing Patent Suits for BreastCancer Tests?, NAT’L J. (Aug. 8, 2013), http://www.nationaljournal.com/healthcare/why-ismyriad-genetics-still-filing-patent-suits-for-breast-cancer-tests-20130808.
78 Auth, supra note 54.
79 Myriad Genetics, Inc., 133 S. Ct. at 2107, 2109.
80 Resnick, supra note 77.
81 Dayrel S. Sewell, Unanimous U.S. Supreme Court and Angelina Jolie: BRCA1 &
BRCA2 Patentability, INTELL. PROP. TODAY 24 (July 2013).
82 Id.
83 Id.
84 Id.
85 Samuel B. Adams & Carl A. Morales, Myriad’s Possible Impact on Patent Eligibility
of
Isolated
non-DNA
Chemical
Substances
(June
19,
2013),
http://www.lexology.com/library/detail.aspx?g=bdf4bfc3-2349-4c4d-bd23-d1d80d1467f0.
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impure materials because there is a difference between pure and impure
materials,” suggesting purified substances from natural sources may be
patent-eligible.86 To the extent these guidelines support patentability of a
small molecule or protein isolated or purified from a natural source, and
to the extent that the USPTO has previously granted claims to such
substances, Myriad suggests that these current and past practices by the
agency may not be entitled to deference.87
Just hours after the Myriad decision was released, the USPTO
circulated a memorandum to all patent examiners.88 The memorandum
advised that, “[e]xaminers should now reject product claims drawn solely
to naturally occurring nucleic acids or fragments thereof, whether isolated
or not, as being ineligible subject matter under 35 U.S.C. § 101.” 89
Although that particular piece of guidance is directly in line with the
Myriad decision, a later sentence highlights uncertainty for the future as
the guidelines recite, “[o]ther claims, including method claims, that
involve naturally occurring nucleic acids may give rise to eligibility
issues and should be examined under the existing guidance in Manual of
Patent Examining Procedure (“MPEP”) 2106, Patent Subject Matter
Eligibility.”90 “Method” claims are another word for “process” claims,
and the USPTO’s statement here concerns patent practitioners and
research institutions because the memorandum mentioned possible
eligibility issues for method claims, despite the fact that the Myriad
holding was expressly limited to non-method claims.91 With this
dichotomy, the USPTO memorandum concludes by stating “[t]he
USPTO is closely reviewing the decision in Myriad and will issue more
comprehensive guidance on patent subject matter eligibility
determinations, including the role isolation plays in those
determinations.”92 On March 4, 2014, the USPTO issued its first guidance
on this issue since Myriad, and issued additional, revised guidance on
December 16, 2014.93
86

Id.
Id.
88 Memorandum from Andrew H. Hirshfeld, Deputy Commissioner for Patent
Examination Policy, for Patent Examining Corps (June 13, 2013), available at
http://www.uspto.gov/patents/law/exam/myriad_20130613.pdf.
89 Id.
90 Id. (emphasis added).
91
Ass’n for Molecular Pathology v. Myriad Genetics, Inc., 133 S. Ct. 2107, 2119 (2013).
92 Memorandum from Andrew H. Hirshfeld (June 13, 2013), supra note 88.
93 2014 Interim Guidance on Patent Subject Matter Eligibility, 79 Fed. Reg. 74618, 74619
87
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B. USPTO Guidance—March 4, 2014
In light of Myriad, the USPTO issued guidance for all claims
reciting or involving laws of nature, natural principles, natural
phenomena, and/or natural products.94 Notably, like all USPTO
memoranda, this is not binding law and either the legislature can enact
superseding statutes or courts can issue overriding opinions.95 The
USPTO expressly stated that “while the holding in Myriad was limited to
nucleic acids, Myriad is a reminder that claims reciting or involving
natural products should be examined for a marked difference under
Chakrabarty.”96 To do so, examiners should refer to the following
flowchart:97

98

(Dec. 16, 2014), available at http://www.gpo.gov/fdsys/pkg/FR-2014-12-16/pdf/201429414.pdf [hereinafter 2014 Interim Guidance]; Memorandum from Andrew H. Hirshfeld
(June 13, 2013), supra note 88.
94 Memorandum from Andrew H. Hirshfeld (Mar. 4, 2014), supra note 8.
95 See, e.g., Myriad Genetics, Inc., 133 S. Ct. at 2107.
96
Memorandum from Andrew H. Hirshfeld (Mar. 4, 2014), supra note 8.
97 Id.
98
Id. at 3.
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This chart illustrates a streamlined patent examination procedure by
clearly defining what does and does not qualify as patent-eligible subject
matter.99 It is no longer a subjective test with an open standard, but rather
an objective one that follows a precise analysis, even with weighing
twelve factors for ascertaining whether something is significantly
different than a judicial exception.100 Interestingly, but perhaps
unsurprisingly, the USPTO did not create this protocol, and in fact it
appears that this analytical framework was derived from Judge Robert W.
Sweet from the Southern District of New York.101 In the first opinion on
the merits in the Myriad case-line, Judge Sweet held that fifteen of
Myriad’s claims spanning seven patents were invalid under 35 U.S.C. §
101, and issued a declaratory judgment against Myriad.102 Judge Sweet’s
analysis of the claims followed the above structure.103
Because the isolated DNA molecules were considered a
composition of matter, and fell under the judicial exceptions as a product
of nature, Judge Sweet analyzed whether the isolated DNA was markedly
different from native DNA.104 Judge Sweet opined that the isolated DNA
was not markedly different from native DNA, and could not be markedly
different because of the very nature of DNA. 105 The claims to isolated
BRCA1 and BRCA2 DNA, in order to serve any importance for genetic
testing, must maintain the “defining characteristic of DNA in its native .
. . form [and this] mandates the conclusion that the challenged
composition claims are directed to unpatentable products of nature.”106
To summarize the flowchart, the first question asks whether a
claimed invention is directed to patentable subject matter under 35 U.S.C.
§ 101, and if it is not, then it cannot be patentable.107 The second question
asks if there is a judicial exception, and if not, then the subject matter is
patent eligible.108 The third question asks if the claim is significantly
different from an unpatentable judicial exception, and thus qualifies as

99
100
101
102
103
104
105
106
107
108

See id. at 3–4.
Id. at 4–5.
See Ass’n for Molecular Pathology v. USPTO, 702 F. Supp. 2d 181 (S.D.N.Y. 2010).
Id. at 211.
Id. at 227–28.
Id.
Id. at 229.
Id.
Memorandum from Andrew H. Hirshfeld (Mar. 4, 2014), supra note 8, at 2.
Id. at 3.
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patent-eligible subject matter.109 To analyze whether a claimed invention
is significantly different, there are six factors that weigh in favor of
eligibility and six factors that weigh against eligibility. 110
Factors that weigh toward eligibility (significantly different):
a)Claim is a product claim reciting something that initially appears to be a natural
product, but after analysis is determined to be non-naturally occurring and
markedly different in structure from naturally occurring products.
b)Claim recites elements/steps in addition to the judicial exception(s) that impose
meaningful limits on claim scope, i.e., the elements/steps narrow the scope of the
claim so that others are not substantially foreclosed from using the judicial
exception(s).
c)Claim recites elements/steps in addition to the judicial exception(s) that relate
to the judicial exception in a significant way, i.e., the elements/steps are more
than nominally, insignificantly, or tangentially related to the judicial exception(s).
d)Claim recites elements/steps in addition to the judicial exception(s) that do
more than describe the judicial exception(s) with general instructions to apply or
use the judicial exception(s).
e)Claim recites elements/steps in addition to the judicial exception(s) that include
a particular machine or transformation of a particular article, where the particular
machine/transformation implements one or more judicial exception(s) or
integrates the judicial exception(s) into a particular practical application. (See
MPEP 2106(II)(B)(1) for an explanation of the machine or transformation
factors).
f)Claim recites one or more elements/steps in addition to the judicial exception(s)
that add a feature that is more than well-understood, purely conventional or
routine in the relevant field.
Factors that weigh against eligibility (not significantly different):
g)Claim is a product claim reciting something that appears to be a natural product
that is not markedly different in structure from naturally occurring products.
h)Claim recites elements/steps in addition to the judicial exception(s) at a high
level of generality such that substantially all practical applications of the judicial
exception(s) are covered.
i)Claim recites elements/steps in addition to the judicial exception(s) that must be
used/taken by others to apply the judicial exception(s).
j)Claim recites elements/steps in addition to the judicial exception(s) that are
well-understood, purely conventional or routine in the relevant field.
k)Claim recites elements/steps in addition to the judicial exception(s) that are
insignificant extra-solution activity, e.g., are merely appended to the judicial
exception(s).
l)Claim recites elements/steps in addition to the judicial exception(s) that amount
to nothing more than a mere field of use.111

109
110
111

Id. at 3.
Id. at 4–5.
Id.
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For practical purposes, the USPTO also provides several examples of the
steps examiners should take and conclusions they should reach when
analyzing claim eligibility.112
Not surprisingly, the multi-factor test compliments the Myriad
decision. One factor weighing against eligibility is whether the “[c]laim
is a product claim reciting something that appears to be a natural product
that is not markedly different in structure from naturally occurring
products.”113 Under this analysis, isolated DNA is not patentable because
it is not markedly different from the chromosomal DNA, as both forms
of DNA have identical nucleotide sequences.114 Although there is a
resulting difference in the molecule’s structure, that difference does not
rise to the level of a marked difference.115 Here, the analysis of cDNA
under the twelve eligibility factors is of utmost importance. Even though
the process of making cDNA may very well be routine in the
biotechnology art, the USPTO reasons that cDNA nonetheless has a
nucleotide sequence markedly different from naturally occurring DNA
and is therefore patent-eligible subject matter.116

112
113
114
115
116

Id. at 11–13.
Memorandum from Andrew H. Hirshfeld (Mar. 4, 2014), supra note 8, at 4.
Id. at 5.
Id.
Id. at 5.
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C. USPTO Guidance—December 16, 2014
In response to public feedback from the USPTO’s March 2014
guidance, the USPTO issued renewed guidance on December 16, 2014.117
This renewed guidance includes a new flowchart examiners should
follow when assessing patentability claims:

118

117

Austin Donohue, USPTO Issues New Myriad Guidance, BIOTECHNOW (Dec. 17,
2014),
http://www.biotech-now.org/public-policy/patently-biotech/2014/12/uspto-issuesnew-myriad-guidance#; see 2014 Interim Guidance, supra note 93, at 74618.
118 2014 Interim Guidance, supra note 93, at 74621.
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As the USPTO points out, there are two notable changes between this
flowchart and the previous flowchart:
• All claims (product and process) with a judicial exception (any type) are subject
to the same steps.
• Claims including a nature-based product are analyzed in Step 2A to identify
whether the claim is directed to (recites) a “product of nature” exception. This
analysis compares the nature-based product in the claim to its naturally occurring
counterpart to identify markedly different characteristics based on structure,
function, and/or properties. The analysis proceeds to Step 2B only when the
claim is directed to an exception (when no markedly different characteristics are
shown).119

In other words, the test now inquires in Step 2B as to whether the
additional elements amount to “significantly more” than a judicial
exception as opposed to the prior language of the claim as a whole
reciting something “significantly different” than the judicial exception. 120
While Step 2A appears to remain unchanged textually, an examiner
should apply it to nature-based products by determining whether a naturebased product limitation in a claim needs to be evaluated using a
markedly different characteristic analysis, and performing that analysis if
necessary.121 “This revised analysis represents a change from prior
guidance, because now changes in functional characteristics and other
non-structural properties can evidence markedly different characteristics,
whereas in the [March 2014 guidance] only structural changes were
sufficient to show a marked difference.”122 Importantly,
a product that is purified or isolated, for example, will be eligible when there is a
resultant change in characteristics sufficient to show a marked difference from
the product’s naturally occurring counterpart. If the claim recites a nature-based
product limitation that does not exhibit markedly different characteristics, the
claim is directed to a “product of nature” exception (a law of nature or naturally
occurring phenomenon), and the claim will require further analysis to determine
eligibility based on whether additional elements add significantly more to the
exception.123

From a patentability standpoint, although inquiring “whether additional
elements add significantly more to the exception” is a positive
development that will likely maintain the patentability of genetic tests, “it
119 Compare id., with Memorandum from Andrew H. Hirshfeld (Mar. 4, 2014), supra
note 8, at 2.
120 Compare 2014 Interim Guidance, supra note 93, with Memorandum from Andrew H.
Hirshfeld (Mar. 4, 2014), supra note 8, at 2.
121 Donald Zuhn, USPTO Issues Interim Guidance on Subject Matter Eligibility, PATENT
DOCS (Dec. 16, 2014), http://www.patentdocs.org/2014/12/uspto-issues-interim-guidanceon-subject-matter-eligibility.html.
122 2014 Interim Guidance, supra note 93, at 74623 n.27.
123 Id.
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will be a long time before we see more stability in this area of patent
law.”124 Just one day after issuing this guidance, the Court of Appeals for
the Federal Circuit issued another decision in the Myriad line, discussed
below.125
D. Myriad at Present and the Uncertain Future
Shortly after the Supreme Court decision, Myriad fired back and
filed infringement suits against its competitors. Initially, Myriad filed
lawsuits against Ambry Genetics Corp. and Gene By Gene Ltd., who
began offering BRCA1 and BRCA2 tests for $2,280 and $995
respectively, a price cheaper than the $4,300 Myriad charges.126 Since
those two suits, Myriad also sued BioReference Laboratories, Inc.
(“BioReference”) in Utah federal court alleging that BioReference,
through its genetic sequencing laboratory subsidiary, GeneDx, Inc.,
infringed Myriad’s intellectual property by offering OncoGeneDx, a
comprehensive series of inherited cancer carrier testing, which includes
testing for BRCA1 and BRCA2.127 Myriad later sued Invitae claiming
infringement of claims in eleven patents underlying Myriad’s
BRACAnalysis test for hereditary breast and ovarian cancer risk.128 In
response, Invitae countersued for a declaratory judgment of noninfringement.129 Additionally, Quest Diagnostics (“Quest”) sought a
declaratory judgment that it would not be infringing on Myriad’s patents
by selling tests for the BRCA genes; two weeks later Myriad filed suit
against Quest, too.130 Further, a sixth entity, Counsyl, is currently seeking
124

Id. at 74623; Donohue, supra note 117.
BRCA1- & BRCA2-Based Hereditary Cancer Test Patent Litig. v. Ambry Genetics
Corp., 2014 U.S. App. LEXIS 23692, at *1 (Fed. Cir. Dec. 17, 2014).
126 Resnick, supra note 77.
127 BioReference Laboratories, Inc. Sued by Myriad Genetics, Confident in Its Position,
GLOBENEWSWIRE
(Oct.
22,
2013),
http://globenewswire.com/newsrelease/2013/10/22/582274/10053651/en/BioReference-Laboratories-Inc-Sued-by-MyriadGenetics-Confident-in-Its-Position.html.
128 InVitae Countersues Myriad in Northern California District Court, GENOMEWEB
(Dec. 2, 2013), http://www.genomeweb.com/clinical-genomics/invitae-countersues-myriadnorthern-california-district-court.
129 Id.
130 BioReference Laboratories, Inc. Sued by Myriad Genetics, Confident in its Position:
Company Not Yet Served, but has Been Prepared for an Expected Action, MARKETWATCH
(Oct. 22, 2013, 8:13 AM), http://www.marketwatch.com/story/bioreference-laboratories-incsued-by-myriad-genetics-confident-in-its-position-2013-10-22?reflink=MW_news_stmp;
Myriad Sues Quest Over BRCA1/2 Patents, GENOMEWEB (Oct. 24, 2013),
125
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a declaratory judgment, similar to Quest, that it is not infringing Myriad’s
patents.131 To date, only Ambry and Gene By Gene countersued Myriad
for antitrust violations.132 However, Myriad and Gene By Gene have
since settled their disputes.133 As part of the settlement terms, Gene By
Gene cannot sell its genetic test for BRCA1 and BRCA2 alone, but can
continue to sell its array that tests multiple genes including BRCA1 and
BRCA2.134
Fundamentally, Myriad executives believe that the company
possesses valid patent claims covering what they consider a new
biomarker, new reagents and techniques for analyzing the biomarker, and
new methods for determining a patient’s risk of breast and ovarian cancer
using these reagents and techniques.135 Myriad argues that the 515 valid
claims it still holds relating to the BRCA1 and BRCA2 tests are sufficient
for the issuance of the preliminary injunctions it is seeking against its
competitors.136 To recapitulate, the Supreme Court holding in Myriad
only invalidated five of Myriad’s original 520 claims spanning the many
patents it holds on BRCA1 and BRCA2 genetic testing.137
Despite the fact that Myriad maintains it still holds 515 valid and
enforceable claims in twenty-four patents, its competitors are clearly
fighting back. A spokesperson from Quest stated that the company
expected Myriad’s lawsuit and described it as “merely the latest in a
http://www.genomeweb.com/clinical-genomics/myriad-sues-quest-over-brca12-patents.
131
Counsyl Files for Declaratory Judgment That It’s Not Infringing Myriad’s BRCA
Patent Claims, GENOMEWEB (Sept. 27, 2013), http://www.genomeweb.com/clinicalgenomics/counsyl-files-declaratory-judgment-its-not-infringing-myriads-brca-patent-claims.
132 Brief for Defendant, Univ. of Utah Research Found. v. Ambry Genetics Corp., No.
2:13-cv-00640-RJS (In re BRCA1- & BRCA2-Based Hereditary Cancer Test Patent Litig.),
3 F. Supp. 3d 1213 (D. Utah 2014), available at http://cdn.arstechnica.net/wpcontent/uploads/2013/08/Ambry-Myriad-Antitrust-docs1.pdf; Gene by Gene Joins Ambry in
Countersuit against Myriad Alleging Antitrust Violations, GENOMEWEB (Aug. 15, 2013),
https://www.genomeweb.com/sequencing/gene-gene-joins-ambry-countersuit-againstmyriad-alleging-antitrust-violations.
133 BRCA Patent Owners and Gene by Gene, Ltd. Resolve Patent Suit, MYRIAD (Feb. 7,
2013), http://investor.myriad.com/releasedetail.cfm?ReleaseID=824154.
134 Id.
135 Resnick, supra note 77.
136 Brief for Plaintiff, Univ. of Utah Research Found. v. Ambry Genetics Corp., No. 2:13cv-00640-RJS (In re BRCA1- & BRCA2-Based Hereditary Cancer Test Patent Litig.), 3 F.
Supp.
3d
1213
(D.
Utah
2014),
available
at
http://ia601800.us.archive.org/24/items/gov.uscourts.utd.89779/gov.uscourts.utd.89779.5.0.
pdf [hereinafter Brief for Plaintiff Ambry].
137 Id.
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pattern of behavior toward any test provider that introduces a new option
in BRCA testing that can benefit patients.”138 Quest is apparently
confident that its genetic test does not violate any of Myriad’s claims and
plans to vigorously defend its product.139 Similarly, Invitae asserts that
its genetic test is not covered by any valid claim of a Myriad patent. 140
Invitae also alleges that its comprehensive test offers the sequencing of
over 200 human genes for less than the single Myriad BRCA1/2 test.141
Even more dramatic, Invitae alleges that approximately fifty additional
claims in four of Myriad’s patents should be invalidated because they are
invalid method claims.142 Time will tell which party is indeed correct, and
on what precise grounds. A court’s finding of either infringement or noninfringement necessarily implies a straightforward winner and loser,
unlike the ruling in Myriad where the Supreme Court invalidated just five
claims spanning all of Myriad’s patents, and did not completely divest
Myriad of its patent exclusivity.143 Absent a settlement, one party must
prevail, and the future of the genetic testing industry might be forever
changed. A defeat for Myriad could devastate the industry for many
reasons, one of which is rooted in the AIA and discussed below. But
now, the latest authority on this matter is the Court of Appeals for the
Federal Circuit’s opinion in Ambry.144
Myriad appealed the District Court of Utah’s March 10, 2014
decision denying Myriad’s request for preliminary injunction to halt
Ambry’s sale of BRCA1 and BRCA2 genetic tests.145 The District
138

Myriad Sues Quest Over BRCA1/2 Patents, supra note 130.
InVitae Countersues Myriad in Northern California District Court, GENOMEWEB,
supra note 130.
140 Brief for Plaintiff Ambry, supra note 136 (citing Myriad Patent No. 6,033,857, claim
4) (requiring “(e) amplifying all or part of the BRCA2 gene from said tissue sample using
primers for a specific BRCA2 mutant allele” when Invitae’s tests do not use any such DNA
primers).
141 Complaint at 2, Invitae Corp. v. Myriad Genetics, Inc., No. 3:13-cv-05495-1 (N.D.
Cal. 2013), available at http://patentdocs.typepad.com/files/cand-3-13-cv-05495-1.pdf.
142 Id. see, e.g., claims 2, 3, 5, 8, 13–15, 17–20, 23, 30, and 33 of U.S. Patent No.
5,753,441; claims 3–8 of U.S. Patent No. 6,033,857; claims 32, 33, and 44 of U.S. Patent No.
6,051,379; and claims 1–18 of U.S. Patent No. 6,951,721. Invitae based its allegations on the
Federal Circuit’s holding that was neither appealed to nor decided by the Supreme Court.
143 See Ass’n for Molecular Pathology v. Myriad Genetics, Inc., 133 S. Ct. 2107, 2119
(2013).
144
BRCA1- & BRCA2-Based Hereditary Cancer Test Patent Litig. v. Ambry Genetics
Corp., 2014 U.S. App. LEXIS 23692, at *1 (Fed. Cir. Dec. 17, 2014).
145 Univ. of Utah Research Found. v. Ambry Genetics Corp. (In re BRCA1- & BRCA2139
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Court’s ruling was affirmed on appeal because the claims at issue were
directed to invalid subject matter.146 Myriad asserted six claims spanning
three patents and importantly included two that involved screening
patients covering the method of performing a genetic test.147 The court
first found that parts of those two claims were invalid because they were
directed to the patent-ineligible abstract idea of comparing BRCA
sequences.148
Turning to the remaining parts of those claims, the court found that
the “non-patent-ineligible elements do not add ‘enough’ to make the
claims as a whole patent-eligible.”149 In so finding, the court reasoned the
claimed elements “set forth well-understood, routine, and conventional
activity engaged in by scientists at the time of Myriad’s patent
applications.”150 Simply put, the non-patent-ineligible elements of the
two claims did nothing more than spell out what practitioners already
knew, which was how to compare gene sequences using routine, ordinary
techniques.151 However, the court left open the possibility that Myriad
could have been successful if it instead sought an injunction on one of its
claims that was directed towards a method of detecting alterations where
the alterations were specifically the genetic mutations that Myriad
discovered.152 With the overall patentability of genetic tests still at issue,
the focus now shifts to the ways in which patents can be challenged by
means other than lawsuits in federal courts.
IV. POST-GRANT PROCEEDINGS
A. Overview of the AIA’s New Post-Grant Proceedings
There are several ways third parties can persuade the USPTO to
cancel others’ patents or claims. It is certainly advantageous to contest
patents in the USPTO, as opposed to the federal courts, and even more so
after the AIA. Before the AIA, patent cancellation options available to

Based Hereditary Cancer Test Patent Litig.), 3 F. Supp. 3d 1213, 1277 (D. Utah 2014).
146 BRCA1- & BRCA2-Based Hereditary Cancer Test Patent Litig., 2014 U.S. App.
LEXIS 23692, at *1.
147 Id. at *11–13.
148 Id. at *16–17.
149 Id. at *20.
150 Id.
151
Id.
152 BRCA1- & BRCA2-Based Hereditary Cancer Test Patent Litig., 2014 U.S. App.
LEXIS 23692, at *21–22.
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third parties through the USPTO included: (1) third party prior art
submissions; (2) ex parte reexamination; and (3) inter partes
reexamination.153 Third party prior art submissions allowed for third
parties to submit patents, published patent applications, or printed
publications that may have been relevant to the examination of a patent
application.154 Ex parte reexamination allowed for third parties to
challenge any unexpired patents on the basis of novelty, obviousness, and
claim scope.155 Such challenges were successful upon finding a
substantial new question of patentability. 156 Inter partes reexamination
was very similar to ex parte reexamination, but was a more extensive and
costly proceeding whereby the petitioner prevailed upon proving a
reasonable likelihood of success as to at least one claim, a much lower
burden required for raising a substantial new question of patentability. 157
However, the patent community criticized those options.158 Third party
prior art submissions were simply inadequate, ex parte reexamination was
too narrow in scope and too lengthy in pendency, and inter partes
reexamination was viewed as too risky in light of its estoppel
provisions.159 Also, under the old provisions, there were growing
concerns about using the judicial system to resolve patent disputes in the
United States, including, but not limited to: cost, nearly unlimited
discovery, lay juries, and lengthy pendency. 160
The rollout of the AIA drastically changed these patent cancellation
options. First, third party prior art submissions, now known as preissuance submissions, have been adapted to better provide patent
153

See Prior Art Citations to Office and Ex Parte Reexamination of Patents, 35 U.S.C. §§
301–07 (2012); Inter Partes Review, 35 U.S.C. §§ 311–19 (2012).
154 Gene Quinn, AIA Oddities: Third Party Submissions of Prior Art, IPWATCHDOG
(Sept. 19, 2013, 8:25 AM), http://www.ipwatchdog.com/2013/09/19/aia-oddities-third-partysubmissions-of-prior-art/id=45118/;
Preissuance
Submissions,
USPTO,
http://www.uspto.gov/aia_implementation/faqs-preissuance-submissions.jsp (last visited
Apr. 19, 2014); see 35 U.S.C. § 122(e) (2012); 37 CFR § 1.290 (2014).
155 Comparison
of
Post-Grant
Proceedings,
RATNER
PRESTIA,
http://www.rppostgrant.com/ComparisonCharts/post-grant-review-comparison.html
(last
visited Apr. 19, 2014).
156 Id.
157 Id.
158 See Filipe De Corte, et al., AIA Post-Grant Review and European Oppositions: Will
They Work in Tandem, or Rather Pass Like Ships in the Night?, 14 N.C. J.L. & TECH. 93
(2012).
159 Id. at 96.
160 Quinn, supra note 154.
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examiners with the best possible prior art references.161 Pre-issuance
submissions allow for third parties to accompany their submissions of
patents, published patent applications, or printed publications with a
concise written description of the relevance of those documents. 162
Second, ex parte reexamination, renamed post-grant review (“PGR”), is
fundamentally still in place and is instituted under the same general
standard of review.163 But, there are some key changes that make PGR
better adapted to serve as a quasi-judicial administrative proceeding to
help relieve some of the burden of patent litigation from domestic federal
courts.164 Third, inter partes reexamination has been replaced by inter
partes review (“IPR”).165 Although IPR’s standard of review is
unchanged, IPR can only be initiated on the basis of novelty and
nonobviousness concerns, as opposed to enablement and arguably even
patentability under 35 U.S.C. § 101, which can be raised in PGR.166 Both
IPR and PGR are statutorily designed to be resolved within one year of
their institution, as opposed to the pre-AIA proceedings that would last
two to three years.167
Though estoppel applies to the petitioner in an IPR, only that entity
cannot request or maintain a subsequent proceeding before USPTO with
respect to any challenged patent claim on any ground that was raised or
reasonably could have been raised.168 This leaves open the door for other
third parties to initiate a subsequent IPR.169 Likewise, the petitioner may
not assert in a subsequent action that a claim is invalid on any ground that
was raised or reasonably could have been raised in the IPR.170 Again, that

161 Proposed New Rules Under AIA to Affect Third-Party Submissions of Prior Art,
BRINKS, GILSON & LIONE (May 31, 2012), http://www.brinksgilson.com/news_events/3406proposed-new-rules-under-aia-affect-third-party-submissions-prior-art.
162 Quinn, supra note 154.
163 Id.
164 Id.
165 Post-Grant: Inter Partes Review, FISH & RICHARDSON, http://fishpostgrant.com/interpartes-review/ (last visited Mar. 22, 2014).
166 Id.
167 Comparison of Post-Grant Proceedings, supra note 155.
168 America
Invents Act (AIA) Frequently Asked Questions, USPTO,
http://www.uspto.gov/patent/laws-and-regulations/america-invents-act-aia/america-inventsact-aia-frequently-asked (last visited May 13, 2015).
169 Id.
170 Id.
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provision only impacts the original petitioner.171 These provisions are the
extent of estoppel, and invalidity opinions will absolutely not carry over
between patents. So at least in theory, it is more efficient for a single
court to rule on the invalidity of entire classes of patents than for the
USPTO to issue opinions through post-grant proceedings that
collectively accomplish the same result; thus, it is necessary for the courts
to subsequently decide Myriad’s unsettled litigation.172 The focus now
turns to the precise effects that unsettled litigation will have on both PGR
and IPR.
B. PGR
Congressional hearings between 2001 and 2006 explored the
creation of PGR proceedings where patents are challenged early in life
and on all validity grounds.173 Such a request was called for by the core
intellectual property professional organizations and accompanying
reports and studies.174
At a 2004 House Intellectual Property
Subcommittee hearing, the American Intellectual Property Law
Association (“AIPLA”) Executive Director, Michael Kirk, argued to
authorize post-grant review.175 He believed that testing the validity of a
newly issued patent that is of dubious validity is often prohibitively
expensive or impossible, and the continued existence of such a patent can

171

Id.
Id.
173 See generally Perspectives on Patents: Post-Grant Review Procedures and other
Litigation Reforms: Hearing Before the Subcomm. on Intellectual Prop. of the S. Comm. on
the Judiciary, 109th Cong. (2006); Patent Quality Improvement: Post-Grant Opposition:
Hearing Before the Subcomm. on Courts, the Internet, and Intellectual Prop. of the H. Comm.
on the Judiciary, 108th Cong. (2004) [hereinafter 2004 House hearing]; Patent
Reexamination and Small Business Innovation: Hearing Before the Subcomm. on Courts, the
Internet, and Intellectual Prop. of the H. Comm. on the Judiciary, 107th Cong. (2002);
Patents: Improving Quality and Curing Defects: Hearing Before the Subcomm. on Courts,
the Internet, and Intellectual Prop. of the H. Comm. on the Judiciary, 107th Cong. (2001)
[hereinafter 2001 House hearing].
174 See 2004 House hearing, supra note 173, at 13–16 (statement of James Toupin,
General Counsel, USPTO), 38 (statement of Michael Kirk, Executive Director, AIPLA) (“The
call for an effective, efficient post-grant system to review patents has reached a crescendo. It
is time to act.”), 52 (Letter of Biotechnology Industry Organization) (listing reports and
groups). For a history of the events leading to the enactment of inter partes reexamination in
1999, see 2001 House hearing, supra note 173, at 38 (statement of Michael Kirk, Executive
Director, AIPLA), 46 (statement of Jeffrey Kushan, Powell, Goldstein, Frazer, and Murphy).
175 2004 House hearing, supra note 173, at 32 (statement of Michael Kirk, Executive
Director, AIPLA).
172

SAM BERSE.DOCX (DO NOT DELETE)

2015]

THE PRACTICAL IMPLICATION

11/3/2015 3:50 PM

443

disrupt product development in a field of technology for years.176 Invalid
or overbroad patents both discourage follow-on innovation, preventing
competition, and also raise prices through unnecessary licensing and
litigation.177 Additionally, the “USPTO is a particularly appropriate
venue for making validity determinations in a cost-effective and
technically sophisticated environment.”178 It stands to reason that PGR
serves a significant and substantial purpose.179
Section 6 of the AIA amended Chapter 31’s authorization of inter
partes proceedings and created the new PGR administrative
proceedings.180 The law now allows the Director of the USPTO to
institute PGR proceedings if he finds that the information presented in
the petition and any response “[shows] that there is a reasonable
likelihood that the petitioner would prevail with respect to at least one of
the claims challenged in the petition.”181
For petitions filed on or after March 19, 2013, PGR costs $12,000
plus a $250.00 fee for each claim in excess of twenty within the patent;
the post-institution fee is $18,000 plus a $550.00 fee for each claim in
excess of fifteen within the patent.182 Thus, for $32,750, up to twenty
claims in a single patent can be reviewed in PGR, with an additional cost
of $800 per claim reviewed in excess of twenty. Post-institution fees
represent fees that are paid up front but refunded in the event that the
petitioner’s request for PGR is denied.183
The provision enacted for post-grant proceedings, 35 U.S.C. § 321,
states in part: “[a] petitioner in a post-grant review may request to cancel
176

Id. at 29 (statement of Michael Kirk, Executive Director, AIPLA).
Evolving IP Marketplace: Aligning Patent Notice and Remedies with Competition,
FTC.GOV (Mar. 2011), available at
http://www.ftc.gov/sites/default/files/documents/reports/evolving-ip-marketplace-aligningpatent-notice-and-remedies-competition-report-federal-trade/110307patentreport.pdf.
178 Perspectives on Patents: Harmonization and Other Matters: Hearing Before the
Subcomm. on Intellectual Prop. of the S. Comm. on the Judiciary, 109th Cong. 77 (2005)
(statement of Q. Todd Dickinson, Vice President and Chief Intellectual Property Counsel,
General Electric Co., and former USPTO Director).
179 Ass’n for Molecular Pathology v. Myriad Genetics, Inc., 133 S. Ct. 2107, 2120 (2013).
180 Leahy-Smith America Invents Act, § 314(a), Pub. L. No. 112–29, Sec. 6(a), 125 Stat.
284, 300 (codified as amended in scattered sections of 35 U.S.C.).
181 Id.
182 America Invents Act (AIA) Frequently Asked Questions, supra note 168.
183 Post-Grant Alert: New PTO Fees Effective March 19, 2013, FISH & RICHARDSON
(Mar. 22, 2013), http://fishpostgrant.com/news/post-grant-alert-new-pto-fees-effectivemarch-19-2013/.
177
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as unpatentable [one] or more claims of a patent on any ground that could
be raised under paragraph (2) or (3) of section 282(b) (relating to
invalidity of the patent or any claim).”184 Of particular relevance in the
analysis is 35 U.S.C. § 321(b), which defines the grounds under 282(b). 185
35 U.S.C. § 282(b) states:
(b) Defenses.— The following shall be defenses in any action involving the
validity or infringement of a patent and shall be pleaded:
(1) Noninfringement, absence of liability for infringement or unenforceability.
(2) Invalidity of the patent or any claim in suit on any ground specified in part II
as a condition for patentability.
(3) Invalidity of the patent or any claim in suit for failure to comply with—
(A) any requirement of section 112, except that the failure to disclose the best
mode shall not be a basis on which any claim of a patent may be canceled or held
invalid or otherwise unenforceable; or (B) any requirement of section 251.
(4) Any other fact or act made a defense by this title.186

Limiting the analysis to the specified paragraphs (2) and (3), postgrant proceedings can be brought up against patents for reasons including
“condition[s] for patentability” or violations of 35 U.S.C. § 112 or §
251.187 For the purpose of this discussion, the primary concern is defining
the phrase “a condition for patentability.”
In one prominent view, the Patent Act sets out the conditions for
patentability in sections § 101, § 102, and § 103.188 Much additional
precedent supports this notion.189 In the eyes of the USPTO leadership,
commentators incorrectly state that 35 U.S.C. § 101 is not a condition for
patentability and cannot be grounds for PGR because it is not expressly
stated within the text of 35 U.S.C. § 282(b)(3).190 The USPTO leadership
184

35 U.S.C. § 321 (2012).
Id.
186 Id. § 282(b).
187 Id.
188 See Graham v. John Deere Co. of Kan. City, 383 U.S. 1, 12 (1966) (“The [1952 Patent]
Act sets out the conditions of patentability in three sections. An analysis of the structure of
these three sections indicates that patentability is dependent upon three explicit conditions:
novelty and utility as articulated and defined in § 101 and § 102, and nonobviousness, the new
statutory formulation, as set out in § 103.”).
189 See Aristocrat Techs. Austl. Pty Ltd. v. Int’l Game Tech., 543 F.3d 657, 661 (Fed. Cir.
2008). In addition to allowing for post-grant review under 35 U.S.C. § 112, section 282(b)
also allows for post-grant review on any ground specified in title 35 as “a condition for
patentability.” Id. While 35 U.S.C. §§ 102 and 103 are expressly titled “conditions for
patentability,” 35 U.S.C. § 101 is generally also considered to be a condition for patentability,
and thus appears to be a ground under which a petitioner can assert invalidity in a post-grant
review. Id.
190 David Kappos, PTAB and Patentability Challenges, DIRECTOR’S FORUM: A BLOG
FROM
USPTO’S
LEADERSHIP
(Sept.
24,
2012,
4:44
PM),
185
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further opines that commentators incorrectly assert that because 35
U.S.C. § 101 is not included in § 282(b)(2), it is not “specified in part II
as a condition for patentability” although § 101 is entitled “[i]nventions
patentable,” unlike § 102 and § 103 that are both entitled “[c]onditions
for patentability.”191 This assertion is made even though § 101 is included
“in part II” of Title 35.192 However, the USPTO leadership does not find
that argument persuasive and believes that for the purpose of PGR, 35
U.S.C. § 101 is considered a condition for patentability. 193
The Supreme Court previously held that 35 U.S.C. § 101 is a
condition for patentability.194 In Graham v. John Deere Co. of Kansas
City,195 the Supreme Court stated in dicta that the 1952 Patent Act “sets
out the conditions of patentability in three sections,” citing 35 U.S.C. §
101, § 102, and § 103.196 The Supreme Court also addressed invalidity
under 35 U.S.C. § 101 when it was raised as a defense to an infringement
claim under 35 U.S.C. § 282.197
Additionally, the Federal Circuit expressly rejected the argument
raised by the dissent in Dealertrack, Inc. v. Huber198 that 35 U.S.C. § 101
is not a “condition for patentability” under 35 U.S.C. § 282, stating that
“the defenses provided in the statute, 35 U.S.C. § 282, include not only
the conditions of patentability in 35 U.S.C. §§ 102 and 103, but also those
in 35 U.S.C. § 101.”199 The Federal Circuit in Dealertrack clarified that
the use of the phrase “conditions for patentability” in the titles of 35
U.S.C. §§ 102 and 103, but not 35 U.S.C. § 101, did not change the result;
here, the court relied on the Supreme Court’s pronouncement in
Pennsylvania Department of Corrections v. Yeskey,200 that a statute’s title
“is of use only when it sheds light on some ambiguous word or phrase”
http://www.uspto.gov/blog/director/entry/ptab_and_patentability_challenges.
191 Id.
192 Id.
193 Id.
194 See Mayo Collaborative Servs. v. Prometheus Labs., Inc., 132 S. Ct. 1289, 1305
(2012); Graham v. John Deere Co. of Kan. City, 383 U.S. 1, 12 (1966).
195 Graham, 383 U.S. at 12.
196 Id.
197 Mayo, 132 S. Ct. at 1305.
198 Dealertrack v. Huber, 674 F.3d 1315, 1330 n.3 (Fed. Cir. 2012) (Plager, J., dissenting).
199 Id. (internal quotation marks omitted) (citing Aristocrat Tech. Austl. Pty Ltd. v. Int’l
Game Tech., 543 F.3d 657, 661 (Fed. Cir. 2008)).
200 Pa. Dep’t of Corrs. v. Yeskey, 524 U.S. 206, 212 (1998) (quoting Trainmen v.
Baltimore & Ohio R.R. Co., 331 U.S. 519, 528–29 (1947)).
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in the statute and that it “cannot limit the plain meaning of the text.”201
In additional reflections by the now-retired Chief Judge Rader, he
posited that the Supreme Court long ago held that 35 U.S.C. § 101 is not
a “condition of patentability.”202 Chief Judge Rader acknowledged that
the statute does not list 35 U.S.C. § 101 among the invalidity defenses to
infringement, but instead under 35 U.S.C. § 282.203 As such, while
invalidity for failing to meet a “condition of patentability” is among the
authorized defenses, 35 U.S.C. § 101 is arguably not a “condition of
patentability.”204
Contrary to the views expressed by several judges of the Federal
Circuit, the legislative history of the AIA makes it clear that Congress
instituted the Patent Trial and Appeal Board (“PTAB”) to consider
challenges brought under 35 U.S.C. § 101 in post-grant reviews.205 A
House Committee Report provides that “the post-grant review
proceeding permits a challenge on any ground related to invalidity under
section 282.”206 Likewise, Arizona Senator Jon Kyl included “section 101
invention issues” among those “that can be raised in post-grant review.”207
To summarize, despite the opinions that 35 U.S.C § 101 is not a condition
for patentability, in the view of the USPTO, the PTAB should consider
patentability challenges brought under 35 U.S.C. § 101 in post-grant
reviews.208 Unless the courts or Congress direct the USPTO otherwise,
the USPTO will continue to do exactly that.209
Such a conclusion implies that patents or patent claims can be
canceled by a third party through the USPTO on 35 U.S.C. § 101 grounds
for a fraction of the cost of litigation.210 A 2005 study found that 4,382 of
the 23,688 human genes in the National Center for Biotechnology
Information’s gene database are explicitly claimed as intellectual
201

Trainmen v. Baltimore & Ohio R.R. Co., 331 U.S. at 528–29.
CLS Bank Int’l v. Alice Corp. Pty, 717 F.3d 1269, 1335 (Fed. Cir. 2013) (citing
Diamond v. Diehr, 450 U.S. 175, 189–90 (1981); In re Bergy, 596 F.2d 952, 963 (CCPA
1979) (Section 101 “was never intended to be a ‘standard of patentability,’ the standards, or
conditions as the statute calls them, are in 102 and 103”)).
203 CLS Bank Int’l, 717 F.3d at 1335.
204 Id.
205 H.R. REP. NO. 112-98, at 47 (2011).
206 Id.
207 112 CONG. REC. S157, 1375 (daily ed. Mar. 8, 2011).
208
Kappos, supra note 190.
209 Id.
210 Post-Grant Alert: New PTO Fees Effective March 19, 2013, supra note 183.
202
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property.211 Patents with claims to those 4,382 genes will be safe from
PGR because PGR can only be implemented on patents filed after March
16, 2013. However, future patents issued are now possibly at risk for
being invalidated through PGR after Myriad.212 PGR could be instituted
for a patent if the twelve factors examiners consider when reviewing
patent applications under 35 U.S.C. § 101 demonstrate that it is “more
likely than not that at least one claim is unpatentable.”213 Therefore, a
third party showing that a greater number of factors weigh against
patentability rather than for patentability is sufficient to invalidate a
patent via PGR.214
C. IPR
Amended by the AIA, 35 U.S.C. § 311 defines IPR’s scope as: “[a]
petitioner in an inter partes review may request to cancel as unpatentable
1 or more claims of a patent only on a ground that could be raised under
section 102 or 103 and only on the basis of prior art consisting of patents
or printed publications.”215 Therefore, IPR cannot be directed to 35
U.S.C. § 101.216 As such, Myriad does not provide a basis for patent
invalidation in an IPR because the holding that DNA sequences are
unpatentable subject matter is not within the scope of an IPR. As a result,
Myriad has no notable effect on IPR because the Myriad holding
implicated changes to the scope of patentable subject matter with respect
to 35 U.S.C. § 101, and none of the other conditions for patentability. 217
Presently, post-Myriad, relevant considerations include how the new
post-grant proceedings will impact existing and future patents. However,
with the AIA, Myriad has a more profound effect on patents issued from
applications filed after March 16, 2013 because of PGR.218 But, this is
expressly under the condition that a PGR must be requested on or prior

211 See Kyle Jensen & Fiona Murray, Intellectual Property Landscape of the Human
Genome, 310 SCI. 239–40 (Oct. 14, 2005).
212 35 U.S.C. § 321 (2012).
213 Comparison of Post-Grant Proceedings, supra note 155.
214 Id.
215 35 U.S.C. § 311 (2012).
216 Id.
217
See generally Ass’n for Molecular Pathology v. Myriad Genetics, Inc., 133 S. Ct. 2107
(2013).
218 America Invents Act (AIA) Frequently Asked Questions, supra note 168.
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to nine months after patent issuance.219 For newly issued patents, there is
a nine-month window in which a PGR can be filed, and after that ninemonth window, only an IPR can be filed.220 As a result, the terms of the
statutes will only allow a 35 U.S.C. § 101 cause of action to be brought
in a PGR, and not in an IPR.221 Therefore, for IPR to invalidate patents to
genes or genetic testing, for example, case law would need to evolve such
that something previously patentable is now unpatentable in light of
either 35 U.S.C. §§ 102 or 103 for lack of novelty or obviousness. The
case law could feasibly evolve in that way, and the post-Myriad future is
discussed below.
V.

THE FUTURE OF GENETIC TESTING IN A POST-MYRIAD WORLD
A. Myriad Defeat in Ambry
In addition to the landmark Myriad decision finding that patent
claims to genes covered ineligible subject matter, the Federal Circuit took
that one step further and held that DNA primers, as compositions of
matter, were not patentable.222 Although cDNA is patentable on the
grounds that a lab technician “unquestionably creates something new,”
the court found primers unpatentable despite the fact they are nonnaturally occurring.223 The court distinguished the two cases by
explaining, “‘separating [DNA] from its surrounding genetic material is
not an act of invention.’”224
Myriad was defeated in a second respect, here, because the Court
also deemed its methods of screening to be unpatentable.225 Comparing a
patient’s BRCA1 sequence with that of a wild-type, or normal, nonmutated sequence, and identifying any differences between the two was
considered a “patent-ineligible abstract idea.”226 Although the patented
method required additional steps such as hybridizing the gene probe and
amplifying and sequencing it, the court viewed these techniques as “well219

Id.
Id.
221 35 U.S.C. §§ 282, 311, 321 (2012).
222 BRCA1- & BRCA2-Based Hereditary Cancer Test Patent Litig. v. Ambry Genetics
Corp., 2014 U.S. App. LEXIS 23692, at *8 (Fed. Cir. 2014).
223 Id. at *8 (quoting Ass’n for Molecular Pathology v. Myriad Genetics, Inc., 133 S. Ct.
2107, 2119 (2013)).
224
Id. at *7 (quoting Myriad Genetics, Inc., 133 S. Ct. at 2117).
225 Id. at *17.
226 Id. at *17.
220
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understood, routine, and conventional techniques” that a scientist would
have contemplated “when instructed to compare two gene sequences.” 227
Therein lies the turning point that may make some fearful of the future.
While Myriad itself might not be terribly affected as its patents
expire over the next several years, courts could invalidate patents of other
patent holders with claims to genetic tests for reasons similar to those in
Ambry, likely before the Myriad litigation even ends and potentially
before settlements are reached.228 For example, as the court found that at
least part of Myriad’s genetic test is unpatentable in accordance with 35
U.S.C. § 101, it might not be that great of a stretch for a court, or the
USPTO, to find that another genetic test is rendered obvious and
unpatentable under 35 U.S.C. § 103.229 Such a holding implies that a
previously undiscovered genetic sequence cannot provide the basis for a
previously known process using the previously unknown genetic
sequence. Because of this, it is possible that the genetic testing industry
would come to a grinding halt as companies’ patents could be brought
into PGR so long as they were issued within the past nine months.
Amendments to patents both during and after the PGR proceedings
are severely restricted and although a PTAB ruling is appealable to the
Federal Circuit, a final decision to reject some or all patent claims does
not mean that patent prosecution is reopened.230 As a result, a patent
owner’s lack of a second chance to secure patentability over what was
once patent-eligible subject matter means that anyone can freely use
subject matter that was once patented by the company, which devoted
substantial amounts of money and time to an invention, simply because
patent law evolved after patents were obtained.231 By experiencing such
an occurrence, or even facing the mere threat of it, companies could stop
227

Id. at *21.
Turna Ray, In Warning to Would-be Competitors, Myriad and BRCA Test Patent
Holders Sue Ambry, Gene by Gene, GENOMEWEB (July 10, 2013),
http://www.genomeweb.com/clinical-genomics/warning-would-be-competitors-myriad-andbrca-test-patent-holders-sue-ambry-gene.
229 35 U.S.C. §§ 101, 103 (2012); Ambry Genetics Corp., 2014 U.S. App. LEXIS 23692,
at *8.
230 See MANUAL OF PATENT EXAMINING PROCEDURE § 1216.01 (9th ed. 2014); Lawrence
Stahl & Donald Heckenberg, The Limited Ability of a Patent Owner to Amend Claims and
Present New Claims in Post-Grant and Inter Partes Reviews, FITZPATRICK, CELLA, HARPER
&
SCINTO,
http://www.fitzpatrickcella.com/DB6EDC/assets/files/News/Fitz_PTO_1_5_8.pdf
(last
visited Mar. 1, 2015).
231 See Ray, supra note 228.
228
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filing patents for genetic tests. More importantly, companies could stop
investing in research for the development of new genetic tests. Although
hindering research is precisely what Dr. Watson wanted to avoid, it is
ironically the consequence of a dramatic court ruling that invalidates
arguably necessary patents.232
Representatives of Myriad adamantly declared, “[t]o create tests for
hereditary breast cancer and ovarian cancer, our company and its
investors spent more than $500 million over 17 years before we were able
to recoup this investment.”233 While it is unclear how much of that money
was used to develop the various aspects of Myriad’s BRCAnalysis test,
one can safely assume that Myriad would not have invested such a sum
if it could not have recouped its investment, and ultimately profited, by
virtue of the exclusive rights granted by patents.234
B. Impact of Future Myriad Loss on Post-Grant Proceedings
In the event Myriad again loses in subsequent litigation, any
arguments asserted against its patents’ validity could then be used,
generally, with respect to every seemingly applicable patent through
post-grant proceedings—either IPR or PGR. Thus, a loss for Myriad
means a loss for every other patent that could be invalidated for similar
reasons.
The logic of the Court in Prometheus could realistically be applied
by future courts to hold that certain genetic tests, specifically Myriad’s,
are wholly unpatentable subject matter.235 In Prometheus, just as a natural
correlation was found to be unpatentable subject matter when it was
incorporated into a generally known or routine diagnostic test, an
analogous situation may very well exist where a future court decides that
isolated human DNA, as unpatentable subject matter, could not be used
in conjunction with a known diagnostic test to ultimately create
patentable subject matter.236 As a result, any patents granted within the
past nine months containing claims to a similarly situated genetic test
232 Brief for James D. Watson as Amici Curiae Supporting Neither Party, Ass’n of
Molecular Pathology v. USPTO, No. 2010-1406, 689 F.3d 1303 (2012).
233 Peter D. Meldrum, Myriad Genetics: Patents Save Lives, Aid Innovation, USA TODAY
(Apr. 14, 2013 6:59 PM), http://www.usatoday.com/story/opinion/2013/04/14/myriadgenetics-supreme-court-editorials-debates/2082553/.
234
See 35 U.S.C. § 154(a)(2) (2012).
235 See Mayo Collaborative Servs. v. Prometheus Labs., 132 S. Ct. 1289 (2012).
236 See id. at 1305.
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would be directly affected by the new changes to post-grant proceedings
wherein PGR could be instituted under 35 U.S.C. § 101 grounds for
invalidity.237 However, a court may invalidate Myriad’s claims for other
reasons. For instance, a court could hold, falling in line with Ambry, that
using a procedurally known genetic test with what is now unpatentable
isolated human DNA is actually obvious, and therefore unpatentable
under 35 U.S.C. § 103.238 Since the test would be considered unpatentable
under this section, IPR could then potentially be invoked. Therefore, any
patent or claim analogous to what would hypothetically comprise any of
Myriad’s future invalidated patents or claims, could be subject to postgrant review proceedings regardless of when they were actually issued.239
VI. CONCLUSION
Going forward, it is imperative for companies investing time and
money into the development of genetic tests to be able to obtain patents
for their tremendous inventions. Should that cease to be the case, it is
imaginable that most biotechnology companies will move into other more
profitable areas of research and innovation. When that happens, nothing
short of legislative action could fill the void left behind of billions of
dollars of research funding that has been invested or that will be invested
in producing currently patentable inventions.
Fortunately, this grim outcome can be avoided. Courts adjudicating
future cases stemming from the Myriad case-line could feasibly issue
narrow holdings that will not have a broad-sweeping effect on the rest of
the industry. These holdings could be more limited to the facts in the
respective cases and could avoid redefining the law. Hopefully the
industry and the USPTO approach the legislature, or the legislature
intervenes on its own accord, sooner rather than later, so a solution can
be reached before it is too late. At this point, all relevant parties involved
in clarifying and defining the law are seemingly diverging on these issues,
further diminishing the hope of a swift resolution.
Post-grant proceedings fit into the broader picture because they
present cheaper and quicker options for invalidating another’s patent, and
courts must tread carefully and be mindful of those proceedings when

237

See 35 U.S.C. § 282 (2012).
Id. § 103; BRCA1- & BRCA2-Based Hereditary Cancer Test Patent Litig. v. Ambry
Genetics Corp., 2014 U.S. App. LEXIS 23692, at *1 (Fed. Cir. Dec. 17, 2014).
239 35 U.S.C. §§ 282, 311, 321 (2012).
238
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issuing decisions along the Myriad case-line. For better or worse, such
court rulings override the views and the guidance provided by the USPTO
leadership. When the Federal Circuit or the Supreme Court deems once
seemingly patentable subject matter to be patent-ineligible, the USPTO’s
hands are tied and it is bound to harmonize its patent granting practices
with that court’s decision. Until the time when the laws are changed,
courts have the final say, and unfortunately opinions are not always as
predictable as everyone would expect. Although it was largely expected
that the Court in Myriad would find DNA is unpatentable subject matter,
the Ambry decision coming out merely one day after the USPTO’s second
interim guidance was a shocking blow that demonstrates the
extraordinary volatility of patent law practice. With the ever-present
uncertainty after these most unfortuitous events unfolded, Ambry must
not foreshadow a future wherein the patentability of method claims
hinges on the patentability of the underlying elements as compositions of
matter.

